E-ISSN: 1308-5263
Turk J Hematol. Ahead of Print: TJH-82150 | DOI: 10.4274/tjh.galenos.2025.2025.0019
2The First People’s Hospital of Yunnan Province, Department of Integrated TCM & Western Medicine, Yunnan, China
3Kunming Medical University, School of General Practitioners, Yunnan, China
4The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China
Daratumumab, Venetoclax, and Azacitidine in Combination with HAA Regimen as Consolidation Chemotherapy for T-cell Acute Lymphoblastic Leukemia with High CD38 Expression
Lin-sen Feng1, Hui-yuan Li2, Ai Tang3, Meng-li Xu4, San-bin Wang41The Sixth Affiliated Hospital, Kunming Medical University, Yunnan, China; The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China; The People’s Hospital of Yuxi City, Department of Hematology, Yunnan, China; unming Medical University, School of General Practitioners, Yunnan, China2The First People’s Hospital of Yunnan Province, Department of Integrated TCM & Western Medicine, Yunnan, China
3Kunming Medical University, School of General Practitioners, Yunnan, China
4The 920th Hospital of Joint Logistics Support Force, Department of Hematology, Yunnan, China
Corresponding Author: San-bin Wang, China
Manuscript Language: English
Manuscript Language: English
Copyright © 2025 Turkish Journal of Hematology